HPV Vaccine in Canada: Bridging the Gap for Newcomers
"Discover how healthcare providers are tackling the unique challenges in HPV vaccination among Canada's newcomer population."
Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Vaccination against HPV is a powerful tool for preventing strains of the virus that lead to cancers and genital warts. In Canada, while HPV vaccines are offered, uptake remains less than ideal, especially among newcomer populations.
Newcomers—immigrants and refugees—often face unique barriers to accessing healthcare, including vaccinations. These barriers range from financial constraints and language difficulties to cultural beliefs and a lack of familiarity with the Canadian healthcare system. Understanding these challenges is crucial for improving public health outcomes and ensuring equitable access to preventive care.
A recent study delved into the perspectives of Canadian healthcare providers on HPV vaccine uptake among newcomers. The study identifies key barriers and facilitators, offering insights into how healthcare practices and policies can be adapted to better serve this diverse population.
HPV Vaccination Coverage and Prevention
HPV vaccines create an immune response that provides resistance to specific HPV-related disease. The Centers for Disease Control and Prevention recommends vaccination for both males and females aged 11 to 12 years. In 2022, 38.6% of U.S. children aged 9–17 had received at least one HPV vaccine dose, with coverage varying by insurance status: 41.5% among children with private insurance, 37.0% with Medicaid, 30.2% with other government coverage, and 20.7% among uninsured children.
Evidence-Based and Individualized Care
A newcomer study found that 18 of 26 individuals who had decided not to vaccinate their child or remained undecided would accept HPV vaccination if a clinician recommended it. No participant said they would definitely refuse the vaccine following a doctor's recommendation. Evidence concerning vaccination beyond age 26 does not support routine population-level vaccination, but it indicates that selected adults with ongoing or anticipated risk of new HPV exposure may benefit through shared clinical decision-making.
From Discovery to Global Use
HPV vaccination has been available in the United States since 2006. According to St. Jude Research, HPV vaccines have been administered more than 270 million times globally and have been found safe and effective in numerous studies. Historical accounts also describe genital and cutaneous warts as recognized since ancient times, including Hippocrates' description of genital warts around 400 BC.
Key Barriers to HPV Vaccine Uptake Among Newcomers
The study identified several significant barriers that hinder HPV vaccine uptake among newcomers. These include:
- Cost: The financial burden of the HPV vaccine is a major obstacle for many newcomers, who often face financial instability upon arrival in Canada.
- Healthcare Access: Navigating the Canadian healthcare system can be complex. Many are unaware of where to receive vaccines or how to schedule follow-up doses.
- Language Barriers: Communication is key, but language differences limit the ability of healthcare providers to explain the vaccine and obtain informed consent. Resources are not available in multiple languages.
- Knowledge Gaps: Many newcomers lack prior knowledge about HPV, its transmission, and the availability of a vaccine. This is exacerbated by the fact that cervical cancer screening may not be common in their countries of origin.
- Cultural and Religious Concerns: Cultural taboos around discussing sexuality and religious beliefs about premarital sex can lead to hesitancy.
Canada's HPV Indicator Framework
Canada's Human Papillomavirus Indicator Framework is produced by the Public Health Agency of Canada's Centre for Immunization Surveillance and Programs and Centre for Surveillance and Applied Research. The framework is intended to organize indicators related to HPV and vaccination surveillance. Its production by these federal public health and surveillance bodies provides a structured basis for monitoring HPV-related measures in Canada.
Beyond Misinformation
Evidence summarized by Cochrane identifies cost, language, and convenience as practical barriers to HPV vaccination. These barriers can interact with cultural, social, political, and moral contexts across different income settings. This suggests that vaccine hesitancy is rarely explained by misinformation alone.
Schedules, Products, and Uptake
A Cochrane review reported that uptake of HPV vaccination remains low in many countries. It found that bivalent and quadrivalent vaccines given in a three-dose schedule are effective in preventing precancerous cervical lesions in women. The review also noted that simpler schedules with fewer doses, as well as programs that include males, might reduce barriers to vaccination.
Recommendations for a Healthier Future
The study highlights the importance of addressing both access and communication to improve HPV vaccine uptake among newcomers. Publicly funding the HPV vaccine for all eligible individuals and enhancing language- and culturally-appropriate health promotion activities are key steps. By understanding the unique needs of newcomers and tailoring healthcare approaches, Canada can move closer to achieving health equity and preventing HPV-related diseases.
Safety, Effectiveness, and Newcomer Access
The Vaccine Integrity Project's review concludes that HPV vaccines remain highly safe and effective in preventing cervical cancer, precancerous lesions, and persistent HPV infection. The review also identifies emerging evidence supporting the potential effectiveness of a single-dose regimen for key outcomes in women. Research on newcomers reports that cultural and language barriers can limit HPV knowledge, while physician recommendations and culturally and linguistically appropriate resources may support informed decisions and vaccine uptake.
Trust and Health-System Capacity
Research on migrant populations identifies concerns about vaccine safety, cultural beliefs, uncertainty, limited knowledge about HPV or HPV vaccines, negative information, and absent health-care-provider recommendations as factors that can reduce uptake. Separate research on national immunization programs links implementation challenges to broader health-system weaknesses. Reported weaknesses include inconsistent cold-chain capacity, transportation limitations, and limited storage.
Measuring Protection in Practice
Real-world estimates of HPV vaccine effectiveness are used to monitor its impact in clinical and public health practice. A 2025 study searched Medline and EMBASE for research published between 2007 and 2023 that measured effectiveness by age at vaccination. Registry-based studies have initially focused on outcomes such as genital warts and cervical precancer because many years can pass between acquisition of a causal HPV infection and cancer incidence.